[go: up one dir, main page]

WO2011008298A3 - Novel axomadol dosage forms - Google Patents

Novel axomadol dosage forms Download PDF

Info

Publication number
WO2011008298A3
WO2011008298A3 PCT/US2010/002011 US2010002011W WO2011008298A3 WO 2011008298 A3 WO2011008298 A3 WO 2011008298A3 US 2010002011 W US2010002011 W US 2010002011W WO 2011008298 A3 WO2011008298 A3 WO 2011008298A3
Authority
WO
WIPO (PCT)
Prior art keywords
axomadol
dosage forms
treating
active agent
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/002011
Other languages
French (fr)
Other versions
WO2011008298A2 (en
Inventor
Ramesh Sesha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nectid Inc
Original Assignee
Nectid Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nectid Inc filed Critical Nectid Inc
Publication of WO2011008298A2 publication Critical patent/WO2011008298A2/en
Publication of WO2011008298A3 publication Critical patent/WO2011008298A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a slow release dosage form comprising a therapeutically effective amount of at least one form of axomadol, at least one pharmaceutically acceptable excipient wherein the said dosage form is suitable for once or twice daily administration. This invention also provides a method of treating a mammal by administering such slow release dosage forms. The present invention also provides a dosage form comprising a therapeutically effective amount of at least one form of axomadol, at least one pharmaceutically acceptable excipient, and at least one second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSADD, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor for treating a patient in need thereof and a method of treating a human comprising administration of such combination dosage forms of axomadol and at least one second active agent.
PCT/US2010/002011 2009-07-16 2010-07-16 Novel axomadol dosage forms Ceased WO2011008298A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27098609P 2009-07-16 2009-07-16
US61/270,986 2009-07-16

Publications (2)

Publication Number Publication Date
WO2011008298A2 WO2011008298A2 (en) 2011-01-20
WO2011008298A3 true WO2011008298A3 (en) 2011-06-16

Family

ID=43450043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002011 Ceased WO2011008298A2 (en) 2009-07-16 2010-07-16 Novel axomadol dosage forms

Country Status (1)

Country Link
WO (1) WO2011008298A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
RU2493830C2 (en) 2008-01-25 2013-09-27 Грюненталь Гмбх Drug form
CA2735934C (en) 2008-09-05 2014-01-07 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
JP5667183B2 (en) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Controlled release dosage form with heat melt extrusion
RU2567723C2 (en) 2009-07-22 2015-11-10 Грюненталь Гмбх Oxidation stable and breaking resistance dosage form
US20120009261A1 (en) * 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP2014524925A (en) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant tablets that provide immediate drug release
US9358204B2 (en) * 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
JP6117249B2 (en) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102670544B (en) * 2012-06-05 2016-04-06 石家庄四药有限公司 A kind of scheme for lacosamide slow releasing tablet and preparation method thereof
CN102885796A (en) * 2012-07-30 2013-01-23 永光制药有限公司 Lacosamide tablet for treating epilepsy and preparation method for lacosamide tablet
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR101732731B1 (en) * 2013-04-02 2017-05-08 주식회사 바이오파마티스 Pharmaceutical compositions for easy control of releasing pattern of lacosamide or pharmaceutically acceptable salts thereof
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (en) 2013-07-12 2019-12-31 Gruenenthal Gmbh tamper-resistant dosage form containing ethylene vinyl acetate polymer
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103432107A (en) * 2013-08-20 2013-12-11 安徽省先锋制药有限公司 Tapentadol hydrochloride paracetamol orally disintegrating tablet and preparation method thereof
BR112016010482B1 (en) 2013-11-26 2022-11-16 Grünenthal GmbH PREPARATION OF A PHARMACEUTICAL COMPOSITION IN POWDER BY MEANS OF CRYOMING
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP2886116A1 (en) * 2013-12-18 2015-06-24 Biocodex Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modification immediate release capsule formulation containing tapentadol
JP2017516789A (en) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Multiparticulates protected against ethanol overdose
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
CN105412047A (en) * 2015-12-03 2016-03-23 烟台东诚药业集团股份有限公司 Skeleton type memantine hydrochloride slow-release capsule and preparation method thereof
CN109692168A (en) * 2017-10-23 2019-04-30 重庆润泽医药有限公司 The pharmaceutical composition and preparation method thereof for treating senile dementia
WO2023096258A1 (en) * 2021-11-24 2023-06-01 부산대학교 산학협력단 Composition for preventing or treating inflammatory bowel disease, comprising riluzole or novel riluzole derivative as active ingredient
KR102625977B1 (en) * 2021-11-24 2024-01-17 부산대학교 산학협력단 Composition for preventing or treating inflammatory bowel diseases comprising riluzole as an active ingredient
KR102785404B1 (en) * 2022-08-19 2025-03-21 부산대학교 산학협력단 Riluzole derivative and colon targeting composition for preventing or treating inflammatory bowel diseases comprising riluzole derivative as an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20060121113A1 (en) * 2003-07-24 2006-06-08 Gruenenthal Gmbh Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US20080306161A1 (en) * 2007-05-11 2008-12-11 Gruenenthal Gmbh Use of Axomadol for Treatment of Arthrosis Pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20060121113A1 (en) * 2003-07-24 2006-06-08 Gruenenthal Gmbh Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US20080306161A1 (en) * 2007-05-11 2008-12-11 Gruenenthal Gmbh Use of Axomadol for Treatment of Arthrosis Pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIWARI, S. B. ET AL.: "Controlled Release Formulation of Tramadol Hydrochloride Using Hydrophilic and Hydrophobic Matrix System", AAPS PHARMSCITECH, vol. 4, no. 3, 2003, XP055025936, DOI: doi:10.1208/pt040331 *

Also Published As

Publication number Publication date
WO2011008298A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2011008298A3 (en) Novel axomadol dosage forms
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
WO2011157416A3 (en) Transdermal administration of memantine
RU2010107843A (en) BUPROPION HYDROBROMIDE AND ITS THERAPEUTIC APPLICATIONS
MA32200B1 (en) New formulations, tablets consisting of these formulas, their use and method of preparation
MX2010010647A (en) Process for preparing orally administered dabigatran formulations.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
PH12013501341A1 (en) Morphinan compounds
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
MX2011011028A (en) Novel thyroid hormone î² receptor agonist.
NO20100301L (en) Improved brimonidine compositions for the treatment of erythema
EA201390977A1 (en) COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
IN2014DN05869A (en)
UA110013C2 (en) APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
PE20091949A1 (en) SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
MX2011011829A (en) Composition for sustained drug delivery comprising geopolymeric binder.
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
UA94042C2 (en) Use of agomelatine for the preparation of drugs to treat smith magenis syndrome
MX2010011193A (en) Liquid pharmaceutical composition for pain treatment and prevention.
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
Watts et al. SABER®-Bupivacaine Concurrently Reduces Postoperative Pain Intensity and Opioid Use for 72 Hours: Evaluation of CROPIRS Scores

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800171

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10800171

Country of ref document: EP

Kind code of ref document: A2